菲利普莫里斯（Philip Morris）股价遭遇重挫，日内跌幅一度达到7%，创下自今年1月份以来的最低水平。此次股价下跌与一则市场消息密切相关。据路透社报道，美国食品和药物管理局（FDA）针对尼古丁袋产品的快速审批通道计划，其推进速度已明显放缓。这一消息对菲利普莫里斯旗下相关产品的前景蒙上阴影，进而引发投资者抛售，导致股价承压下行。
菲利普莫里斯（Philip Morris）股价遭遇重挫，日内跌幅一度达到7%，创下自今年1月份以来的最低水平。此次股价下跌与一则市场消息密切相关。据路透社报道，美国食品和药物管理局（FDA）针对尼古丁袋产品的快速审批通道计划，其推进速度已明显放缓。这一消息对菲利普莫里斯旗下相关产品的前景蒙上阴影，进而引发投资者抛售，导致股价承压下行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.